DE-CSC
16.6.2020 14:02:12 CEST | Business Wire | Press release
CSC , a world leader in business, legal, tax, and domain security, today released its 2020 Domain Security Report: Forbes Global 2000 Companies from their Digital Brand Services (DBS) division. The report highlights significant shortfalls in enterprise domain security practices, putting organizations’ internet-facing digital assets at risk to threats, including domain name and domain name system (DNS) hijacking, phishing, and other fraudulent activity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005062/en/
According to the report, 83% of Global 2000 organizations have not adopted basic domain security measures such as registry lock, which puts them at risk for domain name hijacking. The report indicates a wide industry disparity in domain security maturity with information technology and media and entertainment industries more likely to embrace available security controls, while industries such as materials and real estate trail behind.
“These security shortfalls are the direct result of not executing proper domain security techniques. Domain security cannot be an afterthought, and there needs to be a conscious effort to make this an intentional and critical part of every company’s overall cyber security posture, especially as criminals evolve their attack methods,” says Mark Calandra, executive vice president for CSC DBS. “As companies move to more online business models, it’s essential to use defense-in-depth practices to proactively manage, secure, and defend the foundational internet-facing components of your digital brand presence.”
Additional highlights from the report include:
- Four out of five Global 2000 companies are severely at risk and exposed to domain name and DNS hijacking due to a lack of registry locks. Unlocked domains are vulnerable to social engineering tactics, which can lead to unauthorized DNS changes and domain name hijacking.
- 53% of the Forbes Global 2000 use retail-grade domain registrars, putting them at greater risk for phishing, social engineering, and attacks while complicating compliance demands. The management of the overall domain name portfolio by a reputable corporate registrar versus a retail registrar will make the adoption of domain security standards much easier to implement and monitor.
- Only 20% of Global 2000 companies use enterprise-grade DNS hosting. Lack of DNS hosting redundancy and using non-enterprise-level DNS providers poses potential security threats like resiliency to distributed denial of service (DDoS) attacks, as well as down time, and revenue loss.
- 97% of the Global 2000 don’t use DNS security extensions (DNSSEC), which means the majority of companies are prone to cache poisoning attacks. Lack of deployment of DNSSEC leads to vulnerabilities in the DNS, which could include an attacker hijacking any step of the DNS lookup process.
- Domain-based message authentication, reporting, and conformance (DMARC) use is only at 39% for the Global 2000 companies. DMARC is an email validation system designed to protect a company’s email domain from being used for email spoofing, phishing scams, and other cyber crime.
A core division of CSC, DBS is the trusted provider of choice for the Forbes Global 2000 and is the only enterprise-class registrar with a comprehensive set of solutions focused on defending businesses from targeted threat vectors to their domain names, DNS, and digital certificates. Moreover, the organization detects and mitigates online brand abuse, infringements, and fraud with the latest machine analysis and scoring technology to perform global enforcement, including takedowns and advanced techniques in internet blocking.
If you’re a member of SANS, to learn more, join CSC and SANS for a webinar Friday, June 19. Register here .
External links:
- Download the report here
- Domain Security Report blog post
- Infographic for Domain Security Report
About CSC
CSC is the trusted provider of choice for the Forbes Global 2000 and the 100 Best Global Brands® in enterprise domain names, domain name system (DNS), digital certificate management, as well as digital brand and fraud protection. As global companies make significant investments in their security posture, CSC can help them understand known security blind spots that exist and help them secure their digital assets. By leveraging CSC’s proprietary solutions, companies can get secure to protect against cyber threats to their online assets, helping them avoid devastating revenue loss, brand reputation damage, or significant financial penalties because of policies like the General Data Protection Regulation (GDPR). CSC also provides online brand protection—the combination of online brand monitoring and enforcement activities—taking a holistic approach to digital asset protection, along with fraud protection services to combat phishing. Headquartered in Wilmington, Delaware, USA, since 1899, CSC has offices throughout the United States, Canada, Europe, and the Asia-Pacific region. CSC is a global company capable of doing business wherever our clients are—and we accomplish that by employing experts in every business we serve. Visit cscdbs.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005062/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
